<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27847245</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Celastrol inhibits dengue virus replication via up-regulating type I interferon and downstream interferon-stimulated responses.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>57</EndPage><MedlinePgn>49-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2016.11.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(16)30435-1</ELocationID><Abstract><AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE AND AIM OF THE STUDY">Tripterygium wilfordii (lei gong teng; Thunder of God Vine), a member of the Celastraceae family, is a medicinal plant used to treat a range of illnesses. Celastrol is a quinone methide triterpene and the most abundant bioactive constituent isolated from the root extracts of T.&#xa0;wilfordii. Previous studies have shown that celastrol exhibits antiviral activity against HIV and SARS-CoV. To date, no investigations of the anti-DENV activity of celastrol have been reported. This work aimed to investigate the anti-DENV effect and possible mechanism of celastrol in&#xa0;vitro and in&#xa0;vivo.</AbstractText><AbstractText Label="METHODS">A four-serotype DENV infection system was performed to determine the anti-DENV effect of celastrol by detecting DENV RNA replication and protein synthesis. The precise anti-DENV replication mechanism of celastrol was clarified using specific RNA silencing and specific inhibitor. In addition, the therapeutic efficacy of celastrol was evaluated by monitoring survival rates and clinical scores in a DENV-infected Institute of Cancer Research (ICR) suckling mouse model.</AbstractText><AbstractText Label="RESULTS">Celastrol inhibited DENV-1, -2, -3, and -4 RNA replication with EC<sub>50</sub> values of 0.19&#xa0;&#xb1;&#xa0;0.09, 0.12&#xa0;&#xb1;&#xa0;0.11, 0.16&#xa0;&#xb1;&#xa0;0.14, and 0.17&#xa0;&#xb1;&#xa0;0.08&#xa0;&#x3bc;M, respectively. This antiviral effect of celastrol was associated with celastrol-induced interferon-&#x3b1; (IFN-&#x3b1;) expression and was attenuated by a specific inhibitor of the JAK-STAT signaling pathway downstream of IFN-&#x3b1; or specific shRNA. Furthermore, celastrol protected ICR suckling mice against life-threatening DENV infection.</AbstractText><AbstractText Label="CONCLUSION">Celastrol represents a potential anti-DENV agent that induces IFN-&#x3b1; expression and stimulates a downstream antiviral response, making the therapy a promising drug or dietary supplement for the treatment of DENV-infected patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jung-Sheng</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chin-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center of Infectious Disease and Signaling Research, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chun-Kuang</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Doctoral Degree Program in Marine Biotechnology, College of Marine Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Yao-Chin</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Hsuan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center of Infectious Disease and Signaling Research, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Ching-Liang</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan; Department of Chinese Medicine, China Medical University Hospital, Taichung 40447, Taiwan; Research Center for Chinese Medicine and Acupuncture, China Medical University, Taichung 40402, Taiwan. Electronic address: clhsieh@mail.cmuh.org.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Ching</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; Research Center for Natural Products and Drug Development, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: jclee@kmu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>L8GG98663L</RegistryNumber><NameOfSubstance UI="C050414">celastrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000833" MajorTopicYN="N">Animals, Suckling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004261" MajorTopicYN="N">DNA Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053978" MajorTopicYN="N">Pentacyclic Triterpenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral interferon response</Keyword><Keyword MajorTopicYN="N">Celastrol</Keyword><Keyword MajorTopicYN="N">Dengue virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27847245</ArticleId><ArticleId IdType="pmc">PMC7113783</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2016.11.010</ArticleId><ArticleId IdType="pii">S0166-3542(16)30435-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., Sankoh O., Myers M.F., George D.B., Jaenisch T., Wint G.R., Simmons C.P., Scott T.W., Farrar J.J., Hay S.I. The global distribution and burden of dengue. Nature. 2013;496(7446):504&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chareonsirisuthigul T., Kalayanarooj S., Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J.&#xa0;General Virol. 2007;88(Pt 2):365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251552</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.W., King K., Tu J., Sanchez M., Luster A.D., Shresta S. The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J.&#xa0;Immunol. 2013;191(8):4194&#x2013;4201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795795</ArticleId><ArticleId IdType="pubmed">24043884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang Y.C., Lin J., Lin Y.S., Wang S., Yeh T.M. Dengue virus nonstructural protein 1-Induced antibodies cross-react with human plasminogen and enhance its activation. J.&#xa0;Immunol. 2016;196(3):1218&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">26712948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalrymple N.A., Cimica V., Mackow E.R. Dengue virus NS proteins inhibit RIG-I/MAVS signaling by blocking TBK1/IRF3 phosphorylation: Dengue virus serotype 1 NS4A is a unique interferon-regulating virulence determinant. mBio. 2015;6(3) e00553&#x2013;00515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4436066</ArticleId><ArticleId IdType="pubmed">25968648</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell J.E., Jr. STATs and gene regulation. Science. 1997;277(5332):1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">9287210</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond M.S., Roberts T.G., Edgil D., Lu B., Ernst J., Harris E. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J.&#xa0;Virol. 2000;74(11):4957&#x2013;4966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110847</ArticleId><ArticleId IdType="pubmed">10799569</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink K., Grandvaux N. STAT2 and IRF9: beyond ISGF3. Jak-Stat. 2013;2(4):e27521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906322</ArticleId><ArticleId IdType="pubmed">24498542</ArticleId></ArticleIdList></Reference><Reference><Citation>Halsey E.S., Marks M.A., Gotuzzo E., Fiestas V., Suarez L., Vargas J., Aguayo N., Madrid C., Vimos C., Kochel T.J., Laguna-Torres V.A. Correlation of serotype-specific dengue virus infection with clinical manifestations. PLoS Negl. Trop. Dis. 2012;6(5):e1638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341333</ArticleId><ArticleId IdType="pubmed">22563516</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S.B. Comment on &#x201c;Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity&#x201d; and &#x201c;Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci. Transl. Med. 2015;7(318) 318le314.</Citation><ArticleIdList><ArticleId IdType="pubmed">26676605</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S.B. 2015. Pathogenesis of Dengue: Dawn of a New Era. F1000Research 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754012</ArticleId><ArticleId IdType="pubmed">26918141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu Y.C., Chen N.C., Chen P.C., Wang C.C., Cheng W.C., Wu H.N. Identification of a small-molecule inhibitor of dengue virus using a replicon system. Arch. Virol. 2012;157(4):681&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">22249364</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.J., Yang Y.C., Lin Y.S., Huang J.H., Liu H.S., Yeh T.M., Chen S.H., Liu C.C., Lei H.Y. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J.&#xa0;Immunol. 2006;176(5):2825&#x2013;2832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang D., Weidner J.M., Qing M., Pan X.B., Guo H., Xu C., Zhang X., Birk A., Chang J., Shi P.Y., Block T.M., Guo J.T. Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J.&#xa0;Virol. 2010;84(16):8332&#x2013;8341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916517</ArticleId><ArticleId IdType="pubmed">20534863</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J.&#xa0;Virol. 1999;73(1):783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC103889</ArticleId><ArticleId IdType="pubmed">9847388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M., Davidson A., Hibbert L., Gruenwald P., Schlaak J., Ball S., Foster G.R., Jacobs M. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J.&#xa0;Virol. 2005;79(9):5414&#x2013;5420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1082737</ArticleId><ArticleId IdType="pubmed">15827155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju S.M., Youn G.S., Cho Y.S., Choi S.Y., Park J. Celastrol ameliorates cytokine toxicity and pro-inflammatory immune responses by suppressing NF-kappaB activation in RINm5F beta cells. BMB Rep. 2015;48(3):172&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4453024</ArticleId><ArticleId IdType="pubmed">25059279</ArticleId></ArticleIdList></Reference><Reference><Citation>Katze M.G., He Y., Gale M., Jr. Viruses and interferon: a fight for supremacy. Nature reviews. Immunology. 2002;2(9):675&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.C., Tseng C.K., Wu Y.H., Kaushik-Basu N., Lin C.K., Chen W.C., Wu H.N. Characterization of the activity of 2'-C-methylcytidine against dengue virus replication. Antivir. Res. 2015;116:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25614455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.C., Tseng C.K., Young K.C., Sun H.Y., Wang S.W., Chen W.C., Lin C.K., Wu Y.H. Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. Br. J. Pharmacol. 2014;171(1):237&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874710</ArticleId><ArticleId IdType="pubmed">24117426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.Y., Lee B.H., Kim N.D., Lee J.Y. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner. J.&#xa0;Ethnopharmacol. 2015;172:254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">26116162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S.P., Wang Q.Y., Noble C.G., Chen Y.L., Dong H., Zou B., Yokokawa F., Nilar S., Smith P., Beer D., Lescar J., Shi P.Y. Ten years of dengue drug discovery: progress and prospects. Antivir. Res. 2013;100(2):500&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">24076358</ArticleId></ArticleIdList></Reference><Reference><Citation>McComb S., Cessford E., Alturki N.A., Joseph J., Shutinoski B., Startek J.B., Gamero A.M., Mossman K.L., Sad S. Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proc. Natl. Acad. Sci. U. S. A. 2014;111(31):E3206&#x2013;E3213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128105</ArticleId><ArticleId IdType="pubmed">25049377</ArticleId></ArticleIdList></Reference><Reference><Citation>McMichael A.J., Woodruff R.E., Hales S. Climate change and human health: present and future risks. Lancet. 2006;367(9513):859&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530580</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison J., Laurent-Rolle M., Maestre A.M., Rajsbaum R., Pisanelli G., Simon V., Mulder L.C., Fernandez-Sesma A., Garcia-Sastre A. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog. 2013;9(3):e1003265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610674</ArticleId><ArticleId IdType="pubmed">23555265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasirudeen A.M., Wong H.H., Thien P., Xu S., Lam K.P., Liu D.X. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl. Trop. Dis. 2011;5(1):e926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014945</ArticleId><ArticleId IdType="pubmed">21245912</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry S.T., Buck M.D., Lada S.M., Schindler C., Shresta S. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog. 2011;7(2):e1001297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040673</ArticleId><ArticleId IdType="pubmed">21379341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu Y.B., Park S.J., Kim Y.M., Lee J.Y., Seo W.D., Chang J.S., Park K.H., Rho M.C., Lee W.S. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg. Med. Chem. Lett. 2010;20(6):1873&#x2013;1876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127101</ArticleId><ArticleId IdType="pubmed">20167482</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar M.I., Richardson J.H., Sanchez-Vargas I., Olson K.E., Beaty B.J. Dengue virus type 2: replication and tropisms in orally infected Aedes aegypti mosquitoes. BMC Microbiol. 2007;7:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797809</ArticleId><ArticleId IdType="pubmed">17263893</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler C., Strehlow I. Cytokines and STAT signaling. Adv. Pharmacol. 2000;47:113&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">10582086</ArticleId></ArticleIdList></Reference><Reference><Citation>Screaton G., Mongkolsapaya J., Yacoub S., Roberts C. New insights into the immunopathology and control of dengue virus infection. Nature reviews. Immunology. 2015;15(12):745&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">26603900</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo W.Y., Ju S.M., Song H.Y., Goh A.R., Jun J.G., Kang Y.H., Choi S.Y., Park J. Celastrol suppresses IFN-gamma-induced ICAM-1 expression and subsequent monocyte adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells. Biochem. Biophys. Res. Commun. 2010;398(1):140&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J.&#xa0;Virol. 2004;78(6):2701&#x2013;2710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC353772</ArticleId><ArticleId IdType="pubmed">14990690</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Loriere E., Lin R.J., Kalayanarooj S.M., Chuansumrit A., Casademont I., Lin S.Y., Yu H.P., Lert-Itthiporn W., Chaiyaratana W., Tangthawornchaikul N., Tangnararatchakit K., Vasanawathana S., Chang B.L., Suriyaphol P., Yoksan S., Malasit P., Despres P., Paul R., Lin Y.L., Sakuntabhai A. High anti-Dengue virus activity of the OAS gene family is associated with increased severity of Dengue. J.&#xa0;Infect. Dis. 2015;212(12):2011&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">26063222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubol S., Masrinoul P., Chaijaruwanich J., Kalayanarooj S., Charoensirisuthikul T., Kasisith J. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J.&#xa0;Infect. Dis. 2008;197(10):1459&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">18444802</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn G.S., Kwon D.J., Ju S.M., Rhim H., Bae Y.S., Choi S.Y., Park J. Celastrol ameliorates HIV-1 Tat-induced inflammatory responses via NF-kappaB and AP-1 inhibition and heme oxygenase-1 induction in astrocytes. Toxicol. Appl. Pharmacol. 2014;280(1):42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25064159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.Y., Chang T.H., Liang J.J., Chiang R.L., Lee Y.L., Liao C.L., Lin Y.L. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 2012;8(6):e1002780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386177</ArticleId><ArticleId IdType="pubmed">22761576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>